|Page (1) of 1 - 04/13/18||email article||print page|
VAXIMM Announces Presentations at Upcoming Industry and Scientific Events(April 13, 2018)
DGAP-News: VAXIMM AG / Key word(s): Conference
VAXIMM Announces Presentations at Upcoming Industry and Scientific Events
Basel (Switzerland) and Mannheim (Germany), April 13, 2018 - VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company will participate in several upcoming events in the second quarter of 2018.
AACR (American Association for Cancer Research) Annual Meeting 2018
Poster #733 / 18: "Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform"
The poster summarizes the immunogenicity and anti-leukemia efficacy of VAXIMM's oral T-cell immunotherapy candidate VXM10 encoding variants of the murine PD-L1 protein. The animal study also describes the systemic immunogenicity of Salmonella-based polyepitope oral vaccines, supporting the design of Salmonella-based neoantigen vaccines.
The abstract is available here.
European Neoantigen Summit 2018
Presentation: "Fast and Cost-Effective Oral Delivery Technology of Personalized T-Cell Vaccines Based on a Live Attenuated Bacteria Platform"
Dr. Heinz Lubenau, Chief Operating Officer of VAXIMM, will present the Company's platform technology based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.
Dr. Lubenau also will participate in the panel, "Advancing Manufacturing Practices for Personalized Cancer Vaccines" taking place on Thursday, April 26th at 2:45 PM CEST.
Dr. Lubenau will give a corporate presentation on Tuesday, May 15th at 11:40 AM CEST.
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM's product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target specific structures of the tumor. VAXIMM's lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer. In addition to VXM01, VAXIMM has a pipeline of complementary development candidates targeting different tumor structures. VAXIMM's investors include BB Biotech Ventures, Merck Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company's development activities. For more information, please see www.vaximm.com.